Med24
diabetes 30. 9. 2026 • 2 min read • U.S. Food and Drug Administration (OpenFDA)

Impavido Miltefosine Silicon Dioxide Cellulose: FDA Clinical Pharmacology, Indications and Prescribing Update

1 INDICATIONS AND USAGE IMPAVIDO (miltefosine) capsules are indicated in adults and adolescents ≥12 years of age weighing ≥ 30 kg for the treatment of: Visceral leishmaniasis caused by Leishmania donovani [see Clinical Trials ( 14.1 )] . Cutaneous leishmaniasis caused by Leishmania braziliensis , Leishmania guyanensis...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Impavido (miltefosine) capsules are indicated for the treatment of visceral leishmaniasis caused by *Leishmania donovani*, cutaneous leishmaniasis caused by *Leishmania braziliensis*, *Leishmania guyanensis*, and *Leishmania panamensis*, and mucosal leishmaniasis caused by *Leishmania braziliensis*. The treatment duration is 28 days.

Dosage and Pharmacokinetics of IMPAVIDO

Patients weighing ≥30 kg are to receive either a 50 mg capsule twice daily for 30-44 kg, or a 50 mg capsule three times daily for 45 kg or greater, administered with food to minimize gastrointestinal adverse reactions. Clinical trials evaluated *Leishmania* species based on epidemiological data, with potential geographic variation in response. The efficacy of miltefosine in treating other *Leishmania* species has not been evaluated. Miltefosine is an anti-leishmanial agent with a long half-life (>6 days), resulting in trough plasma concentrations not reaching a steady state. Maximum concentrations were reached before the next dose in many patients. Distribution studies showed widespread uptake in the kidney, liver, and spleen. Human plasma protein binding was 98%. No in vitro oxidative metabolism was observed.

Sponsored content

Clinical Trial Results

The drug is contraindicated in patients with Sjögren-Larsson syndrome. A randomized, open-label study in India involving 299 patients treated with **IMPAVIDO** and 99 patients treated with amphotericin B deoxycholate demonstrated initial cure rates of 98% in both arms. At 6 months, 29.5% of **IMPAVIDO** recipients and 12.1% of amphotericin B recipients continued to have signs and symptoms, attributed to alternative diagnoses in many cases. Final cure rates were 94% for **IMPAVIDO** and 97% for amphotericin B, with 3.0% of **IMPAVIDO** patients experiencing relapse at 6 months.

Original Scientific Source
U.S. Food and Drug Administration (OpenFDA)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement